Cold Genesys Finds $10M For Cancer Immunotherapy

Santa Ana-based Cold Genesys, a company developing oncolytic immunotherapy products, said last week that it has raised $10M in a Series B funding. The funding came from Ally Bridge Group and WI Harper Group along with Whitesun Healthcare Ventures and Song Hong Fang. Cold Genesys is developing viruses which are designed to selectively replicate in tumors (but not normal tissue) and to elicit an immune response against cancer cells.